DSG Capital Advisors LLC Raises Position in Eli Lilly and Company $LLY

DSG Capital Advisors LLC increased its position in Eli Lilly and Company (NYSE:LLY) by 15.9% during the third quarter, Holdings Channel.com reports. The institutional investor owned 35,298 shares of the company’s stock after purchasing an additional 4,843 shares during the period. Eli Lilly and Company accounts for 4.3% of DSG Capital Advisors LLC’s investment portfolio, making the stock its 4th largest holding. DSG Capital Advisors LLC’s holdings in Eli Lilly and Company were worth $26,932,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in LLY. Vanguard Group Inc. grew its holdings in shares of Eli Lilly and Company by 1.5% in the second quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock valued at $62,680,004,000 after purchasing an additional 1,183,038 shares in the last quarter. Laurel Wealth Advisors LLC lifted its position in Eli Lilly and Company by 78,621.2% during the second quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after purchasing an additional 11,537,661 shares during the last quarter. Norges Bank purchased a new position in shares of Eli Lilly and Company in the 2nd quarter worth $8,827,714,000. Jennison Associates LLC increased its holdings in shares of Eli Lilly and Company by 4.3% in the 2nd quarter. Jennison Associates LLC now owns 5,447,636 shares of the company’s stock worth $4,246,596,000 after buying an additional 226,620 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Eli Lilly and Company by 2.0% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 5,359,653 shares of the company’s stock valued at $4,178,010,000 after buying an additional 103,119 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on LLY shares. Berenberg Bank lifted their price target on Eli Lilly and Company from $830.00 to $950.00 and gave the stock a “hold” rating in a research report on Tuesday, December 2nd. Wall Street Zen upgraded Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 1st. Bank of America cut their target price on Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating on the stock in a research report on Monday, December 15th. HSBC restated a “hold” rating and issued a $1,070.00 price target on shares of Eli Lilly and Company in a research report on Wednesday, December 10th. Finally, BMO Capital Markets reiterated an “outperform” rating on shares of Eli Lilly and Company in a research report on Wednesday, January 14th. Four research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $1,173.91.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong commercial momentum from Lilly’s weight‑loss and diabetes franchise continues to underpin investor bullishness, supporting high revenue and EPS guidance. Up 36%, Is Eli Lilly Still a Buy?
• Positive Sentiment: Clinical and R&D advances — including completion of the pirtobrutinib Phase 1/2 study segment — add upside optionality in oncology/BTK space if later‑stage data hold up. Eli Lilly’s Pirtobrutinib Trial Completion Signals Next Phase in the BTK Inhibitor Race
• Positive Sentiment: Pipeline and strategic tech investment headlines (FDA Breakthrough designation for a candidate plus an AI partnership) support long‑term growth expectations beyond GLP‑1s. Eli Lilly (LLY) Oncology Pipeline and $1B Nvidia (NVDA) AI Partnership Signal Strong 2026 Growth
• Neutral Sentiment: Analyst pieces and stock‑watch coverage note Lilly’s heavy market interest and valuation questions — useful for framing risk/reward but not immediate catalysts. Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: Marketing shifts (focus on “weight stigma”) reflect competitive positioning as GLP‑1 competition heats up; relevant for long‑term brand/market share but not an immediate earnings shock. Eli Lilly’s (LLY) New Marketing Focuses on ‘Weight Stigma’
• Negative Sentiment: The U.S. CMS added multiple Lilly branded drugs to the next cycle of the Medicare Drug Price Negotiation Program, increasing potential downward pressure on future pricing and margins for affected products (including the first Part B reimbursements). US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks
• Negative Sentiment: The American Hospital Association and other hospital groups are urging regulators to block Lilly’s new 340B claims‑data submission policy, creating regulatory/legal uncertainty and potential commercial/frictional headwinds with hospitals. AHA Urges HRSA to Stop Eli Lilly’s New Policy on 340B Hospitals From Going into Effect

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $1,038.23 on Wednesday. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The stock’s fifty day moving average is $1,058.15 and its two-hundred day moving average is $885.09. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95. The company has a market capitalization of $981.52 billion, a PE ratio of 50.79, a price-to-earnings-growth ratio of 0.80 and a beta of 0.35.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The firm had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business’s revenue was up 53.9% on a year-over-year basis. During the same period in the previous year, the firm earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be paid a $1.73 dividend. The ex-dividend date is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s payout ratio is currently 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.